SOFTOX SOLUTIONS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1125 NOK | -22.95% |
|
-48.39% | -96.53% |
| Apr. 18 | Transcript : SoftOx Solutions AS - Special Call | |
| Mar. 20 | SoftOx Solutions AS Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 7.9M 727K | Sales 2022 | 7.11M 654K | Capitalization | 241M 22.16M |
|---|---|---|---|---|---|
| Net income 2021 | -65M -5.98M | Net income 2022 | -71M -6.53M | EV / Sales 2021 | 64.3 x |
| Net cash position 2021 | 56.98M 5.24M | Net cash position 2022 | 6.91M 635K | EV / Sales 2022 | 32.9 x |
| P/E ratio 2021 |
-8.86
x | P/E ratio 2022 |
-3.39
x | Employees | 25 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 96.54% |
More Fundamentals
* Assessed data
More news
Latest transcript on SoftOx Solutions
More press releases
| 1 day | -22.95% | ||
| 1 week | -48.39% | ||
| Current month | -42.01% | ||
| 1 month | -72.22% | ||
| 3 months | -93.30% | ||
| 6 months | -97.50% | ||
| Current year | -96.53% |
1 week
0.11
0.22
1 month
0.110.41
Current year
0.113.99
1 year
0.119.80
3 years
0.1179.70
5 years
0.11116.00
10 years
0.11116.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
Geir Almås
FOU | Founder | - | 12-06-20 |
Harald Sætvedt
DFI | Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Olav Jarlsby
BRD | Director/Board Member | - | 15-04-16 |
Geir Almås
FOU | Founder | - | 12-06-20 |
Adrian Bignami
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 0.1125 | -22.95% | 6,266,218 |
| 24-05-02 | 0.146 | -24.74% | 4,607,465 |
| 24-04-30 | 0.194 | -12.61% | 3,213,416 |
| 24-04-29 | 0.222 | +1.83% | 521,245 |
| 24-04-26 | 0.218 | +2.83% | 349,504 |
Real-time Oslo Bors, May 03, 2024 at 10:45 am EDT
More quotes
SoftOx Solutions AS is a Norway-based medtech and biotech company, that develops products to help fight infections from viruses, biofilm resistance and antimicrobial resistance. It is a developer of infection control solutions for disinfection, wound care and the respiratory tract. The current business segments can be divided into: Wounds, Disinfection and Respiratory. SoftOx Solutions is engaged in the development of a range of products that can be classified as either medical devices or medicinal products for human use. SoftOxâs product portfolio includes such products as SafeDes+, a hand disinfectant for irritated, compromised and eczematous skin. The Company has several subsidiaries, including SoftOx Disinfection AS, SoftOx Defense Solutions AS and SoftOx Denmark AS.
Calendar
2024-09-03
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -96.53% | 5.22M | |
| +8.96% | 105B | |
| -1.43% | 104B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +6.79% | 14.16B | |
| +38.61% | 12.63B |
- Stock Market
- Equities
- SOFTX Stock
